Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?

To: Red Dragon who wrote (873)	1/21/1998 8:25:00 PM
From: Roland Chen	Respond to of 1115

Correction from Lidak !! -------- Lidak Pharmaceuticals Corrects Prior Press Release LA JOLLA, Calif., Jan. 20 /PRNewswire/ -- LIDAK Pharmaceuticals (Nasdaq: LDAKA - news) announced today that its press release of January 15, 1998, relating to a preliminary proposal from HealthMed, Inc. contained mistaken information relating to the number of shares of LIDAK Common Stock sold to HealthMed by David H. Katz, M.D., President and CEO of LIDAK. The Company's January 15, 1998 press release stated that ''Dr. Katz had advised the Company that he has sold approximately 30% of his 1,027,003 shares of Class A Common Stock to HealthMed and agreed to place the balance of his Class A shares and his 234,000 shares of Class B Common Stock in a voting trust with HealthMed as the trustee''. Dr. Katz has advised the Company that he has, in fact, sold 30% of his 1,027,003 shares of Class A Common Stock and 30% of his 234,000 shares of Class B Common Stock to HealthMed and has agreed to place the remainder of his Class A Common Stock and Class B Common Stock in a voting trust with HealthMed as trustee. LIDAK Pharmaceuticals is developing therapeutic products designed to treat virally caused diseases, allergies and asthma, inflammatory disorders and cancer. SOURCE: LIDAK Pharmaceuticals ------------------------- Regards, Roland geocities.com